Melanie Senior
When Biogen Idec Inc. 's flagship multiple sclerosis drug interferon beta (Avonex) was approved in Europe in 1997, the...
Biogen Idec's decision to move its international headquarters from Paris to Switzerland reflects the growing size, and changing structure, of its international business. It also increases Switzerland's already strong allure as Europe's friendliest biotech hub.
Melanie Senior
When Biogen Idec Inc. 's flagship multiple sclerosis drug interferon beta (Avonex) was approved in Europe in 1997, the...